Therapeutisches Vorgehen bei ANCA-assoziierten Vaskulitiden
Author:
- 3 June 2015
- journal article
- abstracts
- Published by Springer Nature in Zeitschrift für Rheumatologie
- Vol. 74 (5) , 388-397
Abstract
Recent data from randomized controlled clinical trials have allowed the development of recommendations for treatment of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV).Keywords
This publication has 55 references indexed in Scilit:
- Clinical Outcomes of Remission Induction Therapy for Severe Antineutrophil Cytoplasmic Antibody–Associated VasculitisArthritis & Rheumatism, 2013
- Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated VasculitidesPLOS ONE, 2012
- Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysisRheumatology, 2011
- Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's)Arthritis Care & Research, 2011
- Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysisAmerican Journal of Kidney Diseases, 2011
- Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody–associated vasculitis: A meta‐analysisArthritis Care & Research, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- Value of anti-infective chemoprophylaxis in primary systemic vasculitis: what is the evidence?Arthritis Research & Therapy, 2009
- EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitisAnnals of the Rheumatic Diseases, 2007
- Wegener Granulomatosis: An Analysis of 158 PatientsAnnals of Internal Medicine, 1992